Shiyao Group's GLP-1 injection has been approved by the FDA to conduct clinical trials in the United States.

According to the announcement of the Hong Kong Stock Exchange, China Resources Pharmaceutical Group Limited has obtained approval from the US Food and Drug Administration to conduct clinical trials in the United States on a GLP-1/GIP receptor biased peptide long-acting injectable. According to the announcement, the approved clinical indication for this trial is weight management in obese or overweight individuals with at least one weight-related comorbidity.